NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	psoriasis
Date of first enrollment	05/03/2012
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : Secukinumab INN of investigational material : Secukinumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Intravenous injection and subcutaneous injection

Outcome(s)

Primary Outcome	PASI 75, IGA
Secondary Outcome	PASI 50/75/90/100, IGA

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	-Subjects must have participated in the study CAIN457A2304 and have achieved a partial response after twelve weeks of treatment with no major protocol deviations. A partial response is defined as having achieved >= PASI 50 but < 75 response.
Exclude criteria	-Forms of psoriasis other than chronic plaque -type -Previous exposure to any biologic drug directly targeting IL-17 or the IL-17 receptor, except secukinumab in study CAIN457A2304